Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Padcev

(PAD-sev)
A drug used alone or with pembrolizumab to treat adults with certain types of urothelial cancer (a type of cancer in the bladder or urinary tract) that have spread or cannot be removed by surgery. It is also being studied in the treatment of other types of cancer. Padcev contains a monoclonal antibody that binds to a protein called nectin-4, which is found on some cancer cells. It also contains an anticancer drug, which may help kill cancer cells. Padcev may also help the immune system kill cancer cells. It is a type of antibody-drug conjugate. Also called enfortumab vedotin.
More Information
Search NCI's Dictionary of Cancer Terms